Asset Details
Do you wish to reserve the book?
EMP2 is a novel therapeutic target for endometrial cancer stem cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
EMP2 is a novel therapeutic target for endometrial cancer stem cells
Do you wish to request the book?
EMP2 is a novel therapeutic target for endometrial cancer stem cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
EMP2 is a novel therapeutic target for endometrial cancer stem cells
2017
Overview
Previous studies have suggested that overexpression of the oncogenic protein epithelial membrane protein-2 (EMP2) correlates with endometrial carcinoma progression and ultimately poor survival from disease. To understand the role of EMP2 in the etiology of disease, gene analysis was performed to show transcripts that are reciprocally regulated by EMP2 levels. In particular, EMP2 expression correlates with and helps regulate the expression of several cancer stem cell associated markers including aldehyde dehydrogenase 1 (ALDH1). ALDH expression significantly promotes tumor initiation and correlates with the levels of EMP2 expression in both patient samples and tumor cell lines. As therapy against cancer stem cells in endometrial cancer is lacking, the ability of anti-EMP2 IgG1 therapy to reduce primary and secondary tumor formation using xenograft HEC1A models was determined. Anti-EMP2 IgG1 reduced the expression and activity of ALDH and correspondingly reduced both primary and secondary tumor load. Our results collectively suggest that anti-EMP2 therapy may be a novel method of reducing endometrial cancer stem cells.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 13/51
/ 13/95
/ 96/100
/ Aldehyde Dehydrogenase 1 Family
/ Analysis
/ Animals
/ Biomarkers, Tumor - genetics
/ Biomarkers, Tumor - metabolism
/ Carcinogenesis - drug effects
/ Endometrial Neoplasms - drug therapy
/ Endometrial Neoplasms - metabolism
/ Endometrial Neoplasms - pathology
/ Etiology
/ Female
/ Gene Expression Regulation, Neoplastic - drug effects
/ Humans
/ Immunoglobulin G - pharmacology
/ Medicine
/ Membrane Glycoproteins - antagonists & inhibitors
/ Membrane Glycoproteins - genetics
/ Membrane Glycoproteins - metabolism
/ Mice
/ Neoplastic Stem Cells - drug effects
/ Neoplastic Stem Cells - metabolism
/ Neoplastic Stem Cells - pathology
/ Oncology
/ Retinal Dehydrogenase - genetics
/ Retinal Dehydrogenase - metabolism
/ Tumors
